KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC.J Immunother CancerPMID 39721752PMC116839142024-Dec-250.90While the record is from a Phase III randomized trial with a drug intervention and original results, it does not report a primary or key secondary time-to-event efficacy endpoint. The analysis is a biomarker study focused on T-cell diversity and its association with response/toxicity, not a Kaplan-Meier or hazard ratio analysis of survival or progression-free survival.待处理
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.Signal Transduct Target TherPMID 39715755PMC116667112024-Dec-240.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up).Br J DermatolPMID 39438067无 PMCID2024-Dec-230.98未发现恶性肿瘤人群证据。待处理
Pharmacokinetic-pharmacodynamic Modelling of NH600001 in Healthy Subjects and Patients Undergoing Gastroscopy.AAPS JPMID 39707020无 PMCID2024-Dec-210.98未发现恶性肿瘤人群证据。待处理
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study.Arthritis Res TherPMID 39709462PMC116628032024-Dec-210.98未发现恶性肿瘤人群证据。待处理
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.J Clin OncolPMID 39279580PMC116544482024-Dec-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39292975无 PMCID2024-Dec-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.J Clin OncolPMID 39361946PMC116522332024-Dec-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。部分完成
Sexual health and healthy relationships for Further Education (SaFE) in Wales and England: results from a pilot cluster randomised controlled trial.BMJ OpenPMID 39806667PMC116673392024-Dec-200.98未发现恶性肿瘤人群证据。待处理
General practitioner advance care planning knowledge and attitudes: ACP-GP cluster-randomised controlled trial.BMJ Support Palliat CarePMID 38925875无 PMCID2024-Dec-190.98未发现恶性肿瘤人群证据。待处理
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.N Engl J MedPMID 39248309无 PMCID2024-Dec-190.98未发现恶性肿瘤人群证据。待处理
Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis in Vietnam.N Engl J MedPMID 39693541无 PMCID2024-Dec-190.98未发现恶性肿瘤人群证据。待处理
Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis.N Engl J MedPMID 39693542无 PMCID2024-Dec-190.98未发现恶性肿瘤人群证据。待处理
Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer.J Patient Rep OutcomesPMID 39694978PMC116558002024-Dec-190.90The publication is from a Phase 3 randomized trial (LIBRETTO-531) in oncology and humans, but it is a psychometric analysis of a patient-reported tolerability measure (GP5). It does not report any survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes required for Kaplan-Meier digitization.待处理
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis.Arthritis Res TherPMID 39702318PMC116570062024-Dec-190.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine.J Clin Endocrinol MetabPMID 38828555PMC116516852024-Dec-180.98未发现恶性肿瘤人群证据。待处理
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study.Signal Transduct Target TherPMID 39690158PMC116526522024-Dec-180.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study.Blood Cancer JPMID 39695117PMC116555482024-Dec-180.95Although the study meets many criteria (oncology, human, randomized, Phase 3, drug intervention, original results), it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The primary endpoint is a categorical response (SVR35 at 24 weeks), and secondary endpoints are also categorical (best response rates, TSS50, anemia improvement). No time-to-event analysis is described or implied.待处理
A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older (STRIDE-6).Clin Infect DisPMID 39082735PMC116508862024-Dec-170.98未发现恶性肿瘤人群证据。待处理
Safety and Immunogenicity of an mRNA-1273 Booster in Children.Clin Infect DisPMID 39158584PMC116508552024-Dec-170.98未发现恶性肿瘤人群证据。待处理
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.Clin Infect DisPMID 39180325PMC116508712024-Dec-170.98未发现恶性肿瘤人群证据。待处理
Symptom Screening Linked to Care Pathways for Pediatric Patients With Cancer: A Randomized Clinical Trial.JAMAPMID 39535768PMC115617212024-Dec-170.95The trial is a Phase III randomized clinical trial in pediatric oncology patients with original results, but it does not involve a drug-containing intervention (the intervention is a symptom screening and care pathway system) and does not have a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, or Kaplan-Meier/HR analysis.待处理
Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis.J Infect DisPMID 38853607PMC116465932024-Dec-160.98未发现恶性肿瘤人群证据。待处理
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.J Infect DisPMID 39225478PMC116465762024-Dec-160.98未发现恶性肿瘤人群证据。待处理
Phase III randomized trial comparing palliative systemic therapy to best supportive care in advanced esophageal/GEJ cancer.Int J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39093841无 PMCID2024-Dec-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy of Radicava® IV (intravenous edaravone) in subjects with differing trajectories of disease progression in amyotrophic lateral sclerosis: Use of a novel statistical approach for post hoc analysis of a pivotal phase 3 clinical trial.J Neurol SciPMID 39531940无 PMCID2024-Dec-150.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.LancetPMID 39581202无 PMCID2024-Dec-140.98未发现恶性肿瘤人群证据。待处理
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.N Engl J MedPMID 39254740无 PMCID2024-Dec-120.98未发现恶性肿瘤人群证据。待处理
Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial.RMD OpenPMID 39672591PMC116473172024-Dec-120.95The study is a randomized Phase 3b trial with drug intervention and original results, but it investigates a non-oncology condition (psoriatic arthritis). Furthermore, the primary/key efficacy endpoints (ACR 20/50 response rates) are not time-to-event outcomes; no Kaplan-Meier or time-to-event analysis is reported.待处理
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.Nat CommunPMID 39663356PMC116349632024-Dec-110.75The record describes a secondary, biomarker-focused analysis (ctDNA detection) within a Phase III randomized trial. While it references the trial's drug intervention and OS endpoint, it is not the original primary efficacy report comparing intervention arms. It is a correlative/prognostic sub-study, which falls under the excluded 'post-hoc subgroup, biomarker-only' category for adjudication of primary trial KM data.待处理
Pooled safety evaluation for a new single-shot live-attenuated chikungunya vaccine†.J Travel MedPMID 39400050无 PMCID2024-Dec-100.98未发现恶性肿瘤人群证据。待处理
Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical Trial.JAMAPMID 39527075PMC115555712024-Dec-100.98未发现恶性肿瘤人群证据。待处理
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.Inflamm Bowel DisPMID 38271613PMC116303492024-Dec-050.98未发现恶性肿瘤人群证据。待处理
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.Inflamm Bowel DisPMID 38459910PMC116302832024-Dec-050.98未发现恶性肿瘤人群证据。待处理
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.Blood疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39197072无 PMCID2024-Dec-050.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women.N Engl J MedPMID 39216091PMC117110152024-Dec-050.98未发现恶性肿瘤人群证据。待处理
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39282896无 PMCID2024-Dec-050.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Liposomal Bupivacaine Use in Third Molar Impaction Surgery: INNOVATE Study.Anesth ProgPMID 39711449PMC116144722024-Dec-040.98未发现恶性肿瘤人群证据。待处理
Bilastine 0.6% Preservative-Free Eye Drops as an Effective Once-Daily Treatment for the Signs and Symptoms of Allergic Conjunctivitis: A Pooled Analysis of 2 Randomized Clinical Trials.J Investig Allergol Clin ImmunolPMID 37732873无 PMCID2024-Dec-030.98未发现恶性肿瘤人群证据。待处理
Osilodrostat treatment in patients with Cushing's disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4).Endocr JPMID 39183039PMC117783892024-Dec-020.95The study investigates osilodrostat for Cushing's disease, an endocrine disorder, not a human malignant neoplasm. It is not an oncology trial.待处理
A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL®) in Indian toddlers.VaccinePMID 39303376无 PMCID2024-Dec-020.98未发现恶性肿瘤人群证据。待处理
A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study.VaccinePMID 39461302无 PMCID2024-Dec-020.98未发现恶性肿瘤人群证据。待处理
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.Clin Cancer ResPMID 39475359PMC116096232024-Dec-020.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。部分完成
Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial.JAMA Netw OpenPMID 39625722PMC116157122024-Dec-020.98未发现恶性肿瘤人群证据。待处理
Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group.Int J Radiat Oncol Biol PhysPMID 38631539无 PMCID2024-Dec-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Dupilumab Improves Health-Related Quality of Life and a Range of Symptoms in Patients With Eosinophilic Esophagitis.Am J GastroenterolPMID 38940435PMC116086162024-Dec-010.98未发现恶性肿瘤人群证据。待处理
Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial.Int J Radiat Oncol Biol PhysPMID 38972465无 PMCID2024-Dec-010.95The trial is a randomized Phase III oncology study in humans with an original result, but it is excluded because the intervention is non-drug (radiation therapy techniques only) and the primary endpoint (freedom from failure at 2 years) is reported as a categorical outcome without time-to-event analysis (Kaplan-Meier, HR, or similar).待处理
Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing-Initial Report of the SABR-Dual Trial.Int J Radiat Oncol Biol PhysPMID 39002849无 PMCID2024-Dec-010.95The record describes the initial report from the Phase I safety cohort of a Phase III trial. While the overall trial design is Phase III and randomized, this specific report is non-randomized and focuses on acute toxicity and quality of life endpoints, not a primary time-to-event efficacy endpoint (e.g., OS, PFS). Additionally, the intervention is radiation-based, not a drug-containing intervention.待处理
Helical Tomotherapy Versus 3-Dimensional Conformal Radiation Therapy in High-Risk Prostate Cancer: A Phase 3 Randomized Controlled Trial.Int J Radiat Oncol Biol PhysPMID 39009322无 PMCID2024-Dec-010.90The study is a Phase III randomized trial in oncology with a time-to-event endpoint (biochemical progression-free survival with HR), but the intervention under investigation is a radiation therapy technique, not a drug. The trial does not compare a drug-containing regimen against another; it compares two radiation delivery methods while both arms receive identical standard androgen deprivation therapy. Therefore, it lacks the required drug intervention for inclusion.待处理
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial.Am J Respir Crit Care MedPMID 39012226PMC116224362024-Dec-010.98未发现恶性肿瘤人群证据。待处理